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Abstract: A universal and consistent stage classification system, 
which describes the anatomic extent of a cancer, provides a founda-
tion for communication and collaboration. Thymic epithelial malig-
nancies have seen little progress, in part because of the lack of an 
official system. The International Association for the Study of Lung 
Cancer and the International Thymic Malignancies Interest Group 
assembled a large retrospective database, a multispecialty interna-
tional committee and carried out extensive analysis to develop pro-
posals for the 8th edition of the stage classification manuals. This 
tumor, node, metastasis (TNM)-based system is applicable to all 
types of thymic epithelial malignancies. This article summarizes the 
proposed definitions of the T, N, and M components and describes 
how these are combined into stage groups. This represents a major 
step forward for thymic malignancies.
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(J Thorac Oncol. 2014;9: S65–S72)
Thymic epithelial malignancies are rare tumors. There have been many obstacles to progress in these diseases. Among 
these has been the lack of an official, consistent stage classi-
fication system put forth by the American Joint Committee on 
Cancer (AJCC) and the Union for International Cancer Control 
(UICC) —the bodies responsible for defining stage classifica-
tion throughout the world. At least 15 different stage classifica-
tion systems have been proposed and used.1 These have been 
largely empirically derived, based on data from small numbers 
of patients. Perhaps the most widely used have been the Masaoka 
classification (derived from data on 91 patients),2 and the Koga 
modification of this (based on 76 patients).3 Even among centers 
using one of these classification systems, often the definitions 
have been interpreted differently because of vague wording, thus 
hampering the ability to collaborate effectively.4
In 2009, both the nascent International Thymic 
Malignancies Interest Group (ITMIG) and the International 
Association for the Study of Lung Cancer (IASLC) recog-
nized the need for a consistent stage classification system for 
thymic malignancies. These organizations formed a partner-
ship to address this, with ITMIG providing the engagement of 
the vast majority of clinicians and researchers active in these 
diseases, and IASLC providing funding for the project and 
statistical analysis and its expertise in developing proposals 
for stage classification from its experience in doing this in 
lung cancer.5 A Thymic Domain of the Staging and Prognostic 
Factors Committee (TD-SPFC) was established collabora-
tively by IASLC and ITMIG (Appendix 6). IASLC led discus-
sions and received approval from AJCC and UICC to develop 
proposals for stage classification of thymic malignancies that 
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would help define thymic stage classification in the 8th edition 
of the stage classification manuals. This article describes the 
stage classification proposals developed by IASLC/ITMIG for 
the AJCC/UICC to consider. These proposals are published in 
advance of formal definition of stage classification so that a 
broader discussion can also be considered as the final classifi-
cation is defined by AJCC/UICC. Additional articles describe 
details of the T, N, and M descriptors that are used in the pro-
posed stage classification.6,7
METHODS
A worldwide retrospective database was created by 
ITMIG, which included cases submitted by North and South 
American, European, and Korean institutions and the Chinese 
Alliance for Research in Thymoma; this was supplemented 
by cases from the Japanese Association for Research in the 
Thymus (JART) and additional cases from the European 
Society of Thoracic Surgeons. Together, this represents the 
collaborative effort of 105 institutions worldwide and includes 
10,808 patients (Appendix 5). Details of this database have 
been described earlier.5
The TD-SPFC strove to develop a stage classification 
that was tumor, node, metastasis (TNM) based, and applicable 
to thymoma as well as thymic carcinoma.5 While recogniz-
ing differences between these tumors, these are offset by the 
benefit of having a single system in a rare disease. Definition 
of dividing lines between T, N, or M categories or stage 
groupings was based partially on the ability to separate prog-
nostically distinct groups. Overall survival (OS) and recur-
rence were assessed as endpoints, recognizing that in thymic 
malignancies, these two outcomes are only partially linked 
(recurrence does not necessarily lead to death and deaths are 
often not due to recurrence). OS was evaluated both in an R0 
resected cohort, which makes a major part of treatment rea-
sonably consistent, as well as in all patients (any R status). 
Cumulative incidence of recurrence (CIR) was assessed in 
R0 patients. However, other factors besides these outcomes 
were considered in defining distinct T, N, and M categories 
and stage groups, since prognosis is impacted by many fac-
tors beyond tumor extent. Priorities included development of 
a system that was simple, applicable to clinical staging, and 
able to be used consistently. The stage classification is meant 
only to describe the anatomic extent of disease; development 
of a prognostic index being reserved for a subsequent effort.5
Statistical analysis of the data was carried out by the 
Cancer Research and Biostatistics organization. OS was esti-
mated by the method of Kaplan and Meier8 and curves were 
compared using the log rank test.9 The cumulative incidence 
of recurrence, which accounts for the presence of the com-
peting risk death,10 was used to estimate recurrence. For both 
OS and CIR, outcome was measured from the date of first 
intervention (as this was the baseline date captured in the data-
base) and patients were censored at the date of last follow-up. 
Cox regression models11 were used to obtain hazard ratios for 
OS and recurrence adjusted for diagnosis (thymoma, thymic 
carcinoma, and others, which included neuroendocrine thy-
mic tumors [NETT]). Although it was of interest to adjust for 
geographic region, we were unable to do this given the final 
stage groupings, because cases with sufficient detail regard-
ing stages IVa and IVb consisted primarily of patients from a 
single region (Japan).
PROPOSED STAGE CLASSIFICATION
The T component of the proposed stage classification 
is divided into four categories (Table 1). These correspond 
to “levels” of involvement, as is discussed in more detail in 
another article.6 A tumor is classified in a particular “level” 
if one or more structures in that level is involved, regardless 
of whether other structures of a lower level are involved or 
not. This approach manages the complexity of many different 
structures that may be involved, either alone or in combination 
with others. In the proposed T classification, encapsulation of 
the tumor is not included, because this did not have a clinically 
significant impact on outcomes among cases in the retrospec-
tive database. Pathologically proven involvement of the peri-
cardium is designated as T2, and several different structures 
are included in the T3 category because they had similar out-
comes. Similarly, T4 includes several structures that represent 
more extensive local invasion of a thymic malignancy.
Lymph node involvement is common in thymic carci-
noma but is relatively uncommon in thymoma. Lymph nodes 
are assigned in two groups according to their proximity to the 
thymus: anterior (perithymic) and deep cervical or thoracic 
nodes. These correspond to an N1 and an N2 staging category 
(Table 2). Involved nodes outside these regions (e.g., axillary, 
subdiaphragmatic) are outside the N category and considered 
a distant metastasis. Further details regarding the N and M 
stage classification are provided elsewhere.7
To achieve clarity and consistency regarding node classi-
fication, ITMIG assigned a workgroup which together with the 
IASLC TD-SPFC developed a node map for thymic maligna-
nies, published in detail elsewhere.12 Representative diagrams 
are shown in Figure 1. The anterior region, corresponding to 
N1, is bordered by the hyoid bone and diaphragm craniocau-
dally, the medial edge of the carotid sheaths and mediastinal 
pleura laterally, the sternum anteriorly, the pericardium and 
great vessels posteriorly in the middle, and extending to the 
level of the phrenic nerves posterolaterally. The deep region 
extends from the edges of the anterior region to the lateral 
TABLE 1.  T Descriptors
Category Definition (Involvement of)a,b
T1
  a Encapsulated or unencapsulated, with or without 
extension into mediastinal fat
  b Extension into mediastinal pleura
T2 Pericardium
T3 Lung, brachiocephalic vein, superior vena cava, chest 
wall, phrenic nerve, hilar (extrapericardial)  
pulmonary vessels
T4 Aorta, arch vessels, main pulmonary artery, 
myocardium, trachea, or esophagus
aInvolvement must be pathologically proven in pathologic staging.
bA tumor is classified according to the highest T level of involvement that is present 
with or without any invasion of structures of lower T levels.
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border of the sternocleidomastoid muscle and the anterior edge 
of the vertebral column, and includes jugular, supraclavicular, 
aortopulmonary window, hilar, paratracheal, subcarinal, esoph-
ageal, internal mammary, and supradiaphragmatic nodes.
The M component is divided into three categories 
(Table 2). Absence of tumor outside the primary mass (or 
nodal metastases) is classified as M0. M1a is used to desig-
nate pleural or pericardial nodules (this does not include direct 
extension of the primary tumor into the pleural or pericardial 
space). M1b designates pulmonary intraparenchymal nodules 
or distant metastases (to extrathoracic organs or sites).7
The TNM categories are organized into distinct stage 
groups as shown in Table 3 and Figures 2 to 4. Stages I, II, 
IIIa, and IIIb are determined primarily by the T component. 
Stages IVa and IVb are determined by the presence of N1 or 
M1a disease for IVa and N2 or M1b disease for IVb.
There were many more patients for analysis in the lower 
stages, consistent with the fact that most patients with thymic 
malignancies present with locally confined tumors and the fact 
that data were available predominantly in resected patients. 
Table 4 lists the numbers of patients and events that were 
available for analysis in the various stage groups, along with 
the overall rate of recurrence or death. A progressive increase 
by stage in the overall rate of recurrence and death is generally 
observed. This is particularly apparent for recurrence in the 
lower stages and for OS in any R patients in advanced stages, 
consistent with the assessment that recurrence (in R0 patients) 
is a better marker of the impact of disease in the lower stages 
and OS (in any R patients) in the more advanced stages. For 
some of the groups (particularly in stages IIIb, IVa, and IVb), 
the number of patients is limited, hampering a robust analysis. 
Furthermore, these data are skewed because the database con-
tained very few patients who were not resected; the IIIb, Iva, 
and especially IVb cohorts likely represent highly selected 
patients who were considered amenable to resection.
Definition of the T, N, and M categories and stage groups 
was based heavily on analysis of outcomes. However, there 
was variability between geographic regions and histologic 
types. Therefore, Cox proportional hazards regression models 
were constructed, adjusted by diagnosis (Table 5). Outcome 
curves are shown in Supplemental Figure 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A657). In gen-
eral, a progression of outcomes was seen; each of the analyses 
offers a different view with advantages and disadvantages. 
Recurrence is probably the best measure in less advanced 
tumors.13 Survival in all patients regardless of resection status 
may be best in more advanced tumors, although the number 
of patients is limited. The stage groupings were determined 
using a combination of these outcomes as well as practical and 
anatomic considerations.
The proposed stage classification scheme is applicable 
to both thymoma and thymic carcinoma(TC). Recurrence and 
OS tables and curves were constructed for these histologic 
types and demonstrated similar progression of worsening out-
comes as in the entire patient cohort (Supplemental Tables 1 
and 2 [Supplemental Digital Content 2, http://links.lww.com/
JTO/A658] and Supplemental Figures 2 and 3 [Supplemental 
Digital Content 3, http://links.lww.com/JTO/A659, and 
Supplemental Digital Content 4, http://links.lww.com/JTO/
A660]). However, splitting into smaller stage groups by his-
tologic type results in smaller patient cohorts, precluding the 
ability to have sufficient power to evaluate statistical signifi-
cance between individual groups. There were too few NETT 
to analyze separately regarding stage grouping (NETT cases 
were not included in the analyses of TC, only in the analyses 
of all patients). Nevertheless, the proposed stage classification 
system is recommended to be applied to NETT for consis-
tency. This is an area for validation through prospective data 
collection.
TABLE 2.  N and M Descriptors
Category Definition (Involvement of)a
N0 No nodal involvement
N1 Anterior (perithymic) nodes
N2 Deep intrathoracic or cervical nodes
M0 No metastatic pleural, pericardial, or distant sites
M1
  a Separate pleural or pericardial nodule(s)
  b Pulmonary intraparenchymal nodule or distant organ metastasis
aInvolvement must be pathologically proven in pathologic staging.
FIGURE 1.  ITMIG/IASLC node compartments for 
thymic malignancies. Graphic depiction of N1 (ante-
rior region, blue) and N2 (deep region, purple) node 
compartments. A, Level of thoracic inlet; (B) Level 
of aortopulmonary window; (C) Sagittal view. For 
further details, see Bhora et al.12
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DISCUSSION
The TD-SPFC carried out an extensive analysis of a large 
worldwide database to develop a proposed stage classification 
system for the 8th edition of the AJCC/UICC stage classifica-
tion manual. A formally adopted AJCC/UICC stage classifica-
tion for thymic malignancies would be a major step forward in 
these diseases by providing a single standard as a foundation 
for collective assessment of outcomes. Furthermore, the pro-
posed system is a major advance by being based on a careful 
analysis of a large database with thoughtful input from a mul-
tispecialty international panel of experts.
The Masaoka stage classification provided a starting 
point for stage classification in 1981, based on 91 patients. 
Many other classifications and modifications have been pro-
posed, but in general these have been built on the framework 
of the Masaoka system. Indeed, the stage classification pro-
posed by the TD-SPFC also bears some similarities; at the 
same time, there are also significant differences.
One of the prominent differences is omission of a focus 
on whether a tumor is encapsulated or extends into the thymus 
and perithymic fat. This is driven by the fact that analysis of 
the data did not demonstrate a clinically relevant difference 
between these situations. Indeed, this corroborates obser-
vations made by many other authors.14 It appears that the 
previous focus on encapsulation was driven primarily by a 
speculation that this may distinguish benign thymomas; how-
ever, current thinking is that all thymomas are considered 
malignant.15 Furthermore, it is worth noting that the capsule 
is not a normal anatomic structure but is induced somehow by 
the tumor. At any rate, the data demonstrate that the capsule 
has little clinical impact.
Involvement of the mediastinal pleura also appears to 
have little impact in the IASLC/ITMIG database. There is a 
widespread impression among pathologists that it is often dif-
ficult to identify the mediastinal pleura on resected specimens, 
regardless of invasion (verbal communication, 2nd ITMIG 
Pathology workshop, Heidelberg, Germany, December 2–3, 
2011). However, in analyses of data collected by JART, 
involvement of the mediastinal pleura does have an impact on 
freedom from recurrence. After deliberations that are outlined 
in further detail elsewhere,6 the TD-SPFC decided to retain the 
mediastinal pleural involvement as a distinction between T1a 
and T1b for further testing; without such a designation, collec-
tion of sufficient data for further study would be undermined.
The concept of levels of invasion to define T categories 
is a novel feature of the proposed classification.6 This repre-
sents a logical way to deal with the complexity of involve-
ment of various structures alone or in combination, and 
potential under-reporting of involvement of lower level struc-
tures. However, this needs to be tested in further analyses 
because the amount of available data with sufficient details 
was limited. Separation of IIIa and IIIb stage groups appears 
to be logical, but was not able to be robustly tested in the 
available data. The distinction of N1 and N2 node groups is 
supported by data collected by JART, but the amount of data 
is too limited to assess statistical significance.7 Finally, inclu-
sion of subpleural nodules in M1a and intraparenchymal pul-
monary nodules as M1b was speculative, as the available data 
on this detail were too limited to compare outcomes between 
these groups.7
Decisions regarding how to organize cohorts into stage 
groups and definitions of the T, N, and M categories were made 
after extensive deliberations by the TD-SPFC. This relied 
heavily on consideration of outcomes; the amount of impor-
tance given to particular outcomes (e.g., recurrence, survival) 
and cohorts (e.g., R0, histologic type, region) was determined 
by what was judged to be most relevant. Interpretation of the 
data required accounting for limitations in the data and details 
available. Practical applicability and clinical implications 
TABLE 3.  Stage Grouping
Stage T N M
I T1 N0 M0
II T2 N0 M0
IIIa T3 N0 M0
IIIb T4 N0 M0
IVa T any N1 M0
T any N0,1 M1a
IVb T any N2 M0,1a
T any N any M1b
FIGURE 2.  Stages I (T1N0M0) and 
II (T2N0M0). Graphic depiction of 
Stage group I and II. Copyright © 
Aletta Ann Frazier, MD. A, Stage I: 
tumor that is either “encapsulated” 
or extending into the anterior 
mediastinal fat (T1a) or with direct 
involvement of the mediastinal pleura 
(T1b); (B) Stage II. Tumor invading 
the pericardium (either partial or full 
thickness).
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were also considered. Finally, the proposed classification was 
vetted through the general IASLC process of review by all 
domains of the SPFC.
Clearly, the proposed classification system has weak-
nesses and limitations. The available data were heavily 
weighted toward surgical cases—likely representing the 
greater ability of surgeons and pathologists to have collected 
data to contribute. More advanced tumors are probably under-
represented, beyond their simple lower incidence compared to 
earlier stage tumors. Furthermore, the limited availability of 
details despite the unprecedentedly large database means that 
some aspects had to be decided upon primarily by consensus 
after consideration of practical, anatomic and logical factors. 
It is hoped that the prospective data collection that has been 
initiated by ITMIG will overcome this in subsequent updates 
to the stage classification.
The proposed classification is applicable to thymoma, 
as well as thymic carcinoma, as shown by subgroup analy-
sis of the data. Despite the difference in biologic behavior 
between thymoma and thymic carcinoma, and therefore dif-
ferences in prognosis and the proportion of patients in vari-
ous categories, the lines of separation into distinct groups 
appear to be justified in each histologic type. Furthermore, 
there is precedence for applicability of a stage classification 
to tumors with different degrees of aggressiveness (i.e., the 
lung cancer stage classification applies to carcinoid tumors, 
non-small cell lung cancer, and small cell lung cancer). 
Finally, there is a major advantage in the simplicity of hav-
ing one-stage classification for thymic tumors in diseases 
that are already rare and encountered by most clinicians 
only sporadically.
In clinical use, the T, N, and M categories should ide-
ally be recorded, not just the stage group. Doing this facili-
tates further research into details that could not be assessed 
in the retrospective analysis, despite the unprecedented size 
of the database. It is particularly important to record this even 
in patients who do not undergo surgery, since little data are 
available on such patients.
The stage classification system is meant to be a clini-
cally useful classification of the anatomic extent of disease of 
thymic malignancies. While the anatomic extent has a major 
impact on prognosis, and while outcomes were used to judge 
how to organize the cohorts of patients, the stage classification 
cannot serve as a prognostic prediction model. Prognosis is 
complex, being influenced by multiple tumor-related, patient-
related, treatment-related, and environment-related factors.16 
Furthermore, it is dependent on the clinical scenario, the out-
come of interest, and time at which it is assessed; it is also 
FIGURE 3.  Stage IIIa (T3N0M0) 
and IIIb (T4N0M0). Graphic 
depiction of Stage group IIIa, b. 
Copyright © Aletta Ann Frazier, 
MD. A, Tumor invading the lung, 
brachiocephalic vein, superior 
vena cava, chest wall, and phrenic 
nerve; (B) Tumor invading the 
aorta, intrapericardial pulmonary 
artery, myocardium, trachea, and 
esophagus.
FIGURE 4.  Stages IVa and IVb. 
Graphic depiction of Stage group 
IVa, b. Copyright © Aletta Ann 
Frazier, MD. A, Tumor with sepa-
rate pleural or pericardial nodules 
(M1a) or anterior region node 
involvement (N1); (B) Tumor with 
deep region node involvement 
(N2) or distant metastases includ-
ing intraparenchymal pulmonary 
nodules (M1b).
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continually changing over time. The TD-SPFC specifically 
postponed development of a prognostic prediction model 
to be addressed after the stage classification proposals were 
complete.
CONCLUSION
Stage classification is a fundamental aspect of cancer 
care, providing a consistent uniform nomenclature that permits 
communication, collaboration, and application of observed 
results to the care of new patients. The lack of an official stage 
classification system has contributed to the lack of progress 
in thymic malignancies. This report briefly summarizes the 
extensive work conducted by an international multispecialty 
panel with extensive analysis of a worldwide database that is 
unprecedented in thymic malignancies. The proposed T, N, and 
M categories and stage groupings, applicable to thymoma and 
thymic carcinoma, provide a basis for the 8th edition of the 
AJCC/UICC stage classification, due to be defined and pub-
lished in 2016. This marks the first official stage classification 
system based on an extensive statistical analysis.
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TABLE 5.  Differences between Stage Groups (all Diagnoses)
Variable
CIR, R0
(499/4492)a
OS, R0
(595/6226)a
OS, any R
(876/7314)a
HR p HR p HR p
HR vs. adjacent stage
 II vs. I 3.21 <0.0001 2.05 0.0002 2.28 <0.0001
 IIIa vs. II 1.72 0.02 1.03 NS 1.00 NS
 IIIb vs. IIIa 1.30 NS 1.01 NS 0.94 NS
 IVa vs. IIIb 1.67 NS 1.72 NS 2.00 0.02
 IVb vs. IVa 0.77 NS 1.29 NS 1.26 NS
Hazard ratios and statistical differences χ2 by Cox proportional hazards regression 
models, adjusted for diagnosis.
aNumber of events/total number of patients in entire data set for the particular 
analysis.
CIR, cumulative incidence of recurrence; HR, hazard ratio; NS, not significant (p 
values are given if < 0.1); OS, overall survival; R0, complete resection.
TABLE 4.  Total Proportion of Recurrences or Deaths
Recurrences Deaths
Stage % n % n
I 5 192/3659 7 363/5134
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I (T1b) 9 24/276 11 34/319
II 18 22/124 16 30/187
III 32 149/473 18 113/611
IIIa 31 142/455 18 108/588
IIIb 39 7/18 22 5/23
IVa 59 119/201 30 75/251
N1 M0 54 21/39 28 11/40
N0,1  M1a 60 98/162 30 64/211
IVb 49 17/35 33 14/43
N2 M0,1a, x 45 9/20 36 9/25
N0-2,x  M1b 53 8/15 28 5/18
Total 11 499/4492 10 595/6226
The total number of recurrences or deaths observed at any time out of the total 
number of evaluable R0 resected patients in each category.
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